Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Fasting and Fed Conditions
NCT07492173Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of trifluridine and tipiracil in solid tumor (2 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Peak Plasma Concentration at 24 hours, Area under the plasma concentration versus time curve from time 0 to time t at 24 hours and 1 more. Started Nov 2022; status: completed.
02
Drugs
trifluridinetipiracil
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07492173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492173.